PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.

Documenti analoghi

• PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
  di: R. Fonseca, et al.
  Pubblicazione: (2022-06-01)
• Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency
  di: Remy S. Petersen, MD, et al.
  Pubblicazione: (2024-11-01)
• Safety and Efficacy of Low-Dose Triamcinolone Injection without Injection Frequency Limitation for Trigger Finger
  di: Jo Watanabe, MD, PhD, et al.
  Pubblicazione: (2025-03-01)
• Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis
  di: Yoshiki Okada, MD, et al.
  Pubblicazione: (2026-02-01)
• Inhibition of Myeloma Cell Function by Cannabinoid-Enriched Product Associated With Regulation of Telomere and TP53
  di: Ibrahim Musa PhD, et al.
  Pubblicazione: (2024-09-01)